Esperion Therapeutics Missed Consensus Estimates
Tuesday, May 6, 2025 at 6:00 AM ET
Esperion Therapeutics (ESPR) reported a loss of $0.21 per share on revenue of $65.00 million for the first quarter ended March 2025. The consensus estimate was a loss of $0.18 per share on revenue of $57.73 million. The company missed consensus estimates by 16.67% while revenue fell 52.81% compared to the same quarter a year ago.
Esperion Therapeutics Inc is engaged in the research, development and commercialization of therapies for the treatment of patients with elevated levels of elevated levels of LDL-C.
Earnings Whisper Grade
Power Rating
-
-
Reported Earnings
$-0.21
Earnings Whisper®
-
Consensus Estimate
$-0.18
Earnings Surprise
Earnings Growth
Reported Revenue
$65.00 Mil
Revenue Estimate
$57.73 Mil
Revenue Surprise
Revenue Growth